The efficacy of RNA-seq-based endometrial receptivity test (rsERT) in guiding personalized embryo transfer in women with polycystic ovarian syndrome without recurrent implantation failure: a randomized controlled trial

RCT OA: closed
⚙ AI-generated summary by qwen3.7-flash, 2026-10-05 ⓘ

This randomized controlled trial found no significant difference in pregnancy or implantation rates between personalized embryo transfer guided by RNA-seq endometrial receptivity testing and regular frozen embryo transfer in women with polycystic ovary syndrome without recurrent implantation failure.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-11-03 · read from full text ⓘ

This randomized controlled trial evaluated the efficacy of RNA-seq-based endometrial receptivity testing (rsERT) in guiding personalized embryo transfer for women with polycystic ovary syndrome who had not experienced recurrent implantation failure. The study found no statistically significant differences in intrauterine pregnancy, implantation, or ongoing pregnancy rates between patients receiving rsERT-guided transfers and those undergoing regular frozen embryo transfer. Consequently, the authors concluded that current evidence does not support the routine use of rsERT for this specific patient population, citing the need for further large-scale trials. This paper is relevant to endometriosis research only tangentially, as it explicitly excluded patients with stage III–IV endometriosis from its cohort to isolate endometrial factors associated with PCOS.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

PURPOSE: To assess the effectiveness of personalized embryo transfer (pET) in enhancing intrauterine pregnancy rates in women with polycystic ovary syndrome (PCOS) without recurrent implantation failure (RIF). METHODS: This single-center, open-label, randomized controlled trial was conducted at a university-affiliated assisted reproductive medical center between October 2022 and May 2024. Eligible participants were randomly assigned to either the pET arm guided by the RNA-seq-based endometrial receptivity test (rsERT) or the regular frozen embryo transfer (FET) arm. Clinical outcomes from the first embryo transfer cycles following the tests were tracked and compared between the groups. RESULTS: A total of 121 patients were included and randomly assigned to either the FET arm (n = 60) or the pET arm (n = 61). Intention-to-treat analyses revealed no significant differences between the FET group and the pET group in terms of intrauterine pregnancy rate (61.2% vs. 60.0%, difference, - 1.2% [95% CI, - 20.2 to 17.9%], p = 0.901), embryo implantation rate (54.7% vs. 50.7%, difference, - 4.0% [95% CI, - 20.5 to 12.8%], p = 0.643), early miscarriage rate (3.3% vs. 6.7%, difference, 3.3% [95% CI, - 11.1 to 18.7%], p = 1.000), and ongoing pregnancy rate (59.2% vs. 56.0%, difference, - 3.2% [95% CI, - 22.3 to 16.2%], p = 0.749). Subgroup analyses of intrauterine pregnancy rates revealed no statistically significant differences between the groups, regardless of the analysis method used. CONCLUSIONS: Current evidence does not support the routine use of rsERT for personalized embryo transfer in PCOS patients without RIF. Further large-scale, well-designed clinical trials are needed. TRIAL REGISTRATION: The trial was registered on the Chinese Clinical Trial Registry (registration no. ChiCTR2200064131, prospectively registered). Trial registration date: 2022-09-27.
Full text 54,127 characters · extracted from oa-html · 11 sections · click to expand

Abstract

Purpose To assess the effectiveness of personalized embryo transfer (pET) in enhancing intrauterine pregnancy rates in women with polycystic ovary syndrome (PCOS) without recurrent implantation failure (RIF).

Methods

This single-center, open-label, randomized controlled trial was conducted at a university-affiliated assisted reproductive medical center between October 2022 and May 2024. Eligible participants were randomly assigned to either the pET arm guided by the RNA-seq-based endometrial receptivity test (rsERT) or the regular frozen embryo transfer (FET) arm. Clinical outcomes from the first embryo transfer cycles following the tests were tracked and compared between the groups.

Results

A total of 121 patients were included and randomly assigned to either the FET arm (n = 60) or the pET arm (n = 61). Intention-to-treat analyses revealed no significant differences between the FET group and the pET group in terms of intrauterine pregnancy rate (61.2% vs. 60.0%, difference, − 1.2% [95% CI, − 20.2 to 17.9%], p = 0.901), embryo implantation rate (54.7% vs. 50.7%, difference, − 4.0% [95% CI, − 20.5 to 12.8%], p = 0.643), early miscarriage rate (3.3% vs. 6.7%, difference, 3.3% [95% CI, − 11.1 to 18.7%], p = 1.000), and ongoing pregnancy rate (59.2% vs. 56.0%, difference, − 3.2% [95% CI, − 22.3 to 16.2%], p = 0.749). Subgroup analyses of intrauterine pregnancy rates revealed no statistically significant differences between the groups, regardless of the analysis method used.

Conclusions

Current evidence does not support the routine use of rsERT for personalized embryo transfer in PCOS patients without RIF. Further large-scale, well-designed clinical trials are needed. Trial registration The trial was registered on the Chinese Clinical Trial Registry (registration no. ChiCTR2200064131, prospectively registered). Trial registration date: 2022–09-27. Supplementary Information The online version contains supplementary material available at 10.1007/s10815-025-03627-x.

Keywords

Polycystic ovarian syndrome, RNA-seq based endometrial receptivity test, Window of implantation, Personalized embryo transfer

Background

Polycystic ovarian syndrome (PCOS) is a prevalent endocrine disorder affecting 6–15% of women worldwide [1]. The diagnosis relies on two of three main features: ovulatory dysfunction (OD), clinical or biochemical hyperandrogenism (HA), and polycystic ovarian morphology (PCOM) on ultrasound, after excluding other causes [2]. Additional common features include obesity, insulin resistance (IR), and metabolic disorders, which contribute to disease severity. Despite its high prevalence among reproductive-age women, the pathogenesis of PCOS remains multifactorial and not fully understood, posing ongoing challenges for clinical management [3]. Historically, PCOS was suggested to primarily affect the quality and regularity of ovulation. However, even with restored ovulation or the transfer of high-quality embryos, PCOS patients face substantial challenges, including a higher risk of implantation failure, reduced cumulative pregnancy rates, and increased incidence of spontaneous miscarriage [4–6]. The pathophysiology of PCOS is complex and involves factors that compromise both embryonic development and endometrial receptivity. Notably, impaired endometrial function is frequently observed in PCOS, as demonstrated by altered responses across the pre-receptive, receptive, and post-receptive phases of the endometrial cycle [7–9]. Moreover, significant differences were found in the endometrial transcriptome [10, 11] and proteome [12–15] of PCOS women compared to normal controls during the window of implantation (WOI), involving pathways related to metabolism, inflammation, and cell adhesion, collectively leading to disrupted endometrial function. The intricate interplay among hormonal, metabolic, and endometrial factors underscores the need for precise diagnosis and personalized treatment. The WOI represents a narrow time frame during the mid-luteal phase when the endometrium is optimally receptive. Variability in WOI timing, particularly among patients with recurrent implantation failure (RIF), may result in embryo-endometrium asynchrony [16, 17]. In PCOS, dysregulated hormonal and molecular signaling pathways, especially in those with hyperandrogenism and anovulation, can delay or impair decidualization [18–20]. Progesterone resistance in this subgroup further reduces anti-androgenic signaling and compromised stromal differentiation, ultimately compromising implantation potential [21, 22]. Recent advancements in omics-based technologies have accelerated the development of personalized medicine, enabling classification based on transcriptomic signatures. The RNA-seq-based endometrial receptivity test (rsERT) is a transcriptomic tool that identifies the WOI based on endometrial transcriptomic signatures, achieving an average accuracy of 98.4% through tenfold cross-validation [23, 24]. rsERT-guided personalized embryo transfer (pET) has demonstrated improved intrauterine pregnancy outcomes in both RIF and non-RIF patients [23–27]. However, the specific application of this strategy in PCOS populations remains underexplored. In this single-center, randomized controlled trial (RCT), we aimed to investigate the characteristics of the WOI and evaluate the effectiveness of rsERT-guided pET in improving intrauterine pregnancy rates in infertile women with PCOS. To focus specifically on the endometrial factors while ensuring ethical standards, we included non-RIF patients with at least one prior failed IVF attempt.

Methods

Study design The study is a single-center, open-label, randomized controlled trial conducted at the Department of Reproductive Medicine of Xiangya Hospital, Central South University from October 2022 to May 2024. The study protocol as well as the informed consent were approved by the Medical Ethics Committee of Xiangya Hospital (reference number: 202112604–2) and prospectively registered on the Clinical Trial Registry (registration number: ChiCTR2200064131). This study is conducted in accordance with the Declaration of Helsinki. Participants Given the relatively high clinical pregnancy rates in patients with PCOS and the invasive nature of the procedure, participants were recruited after experiencing at least one failed embryo transfer cycle. They were then randomized to either the pET arm or the regular frozen embryo transfer (FET) arm. The inclusion criteria were (i) diagnosed with PCOS according to revised 2003 Rotterdam criteria [2], (ii) aged 20–35, (iii) having embryos frozen in our center, and (iv) willing to participate and sign the informed consent. Patients were excluded for (i) endometrial diseases, such as intrauterine adhesions and endometrial tuberculosis; (ii) uterine malformations; (iii) unsolved severe hydrosalpinx; (iv) stage III–IV endometriosis; (v) other diseases affecting embryo implantation, such as immune system diseases (systemic lupus erythematosus, Sjogren’s syndrome, etc.); (vi) recurrent miscarriage (two or more biochemical pregnancies or spontaneous abortions), repeated implantation failure (three or more failed in vitro fertilization [IVF] cycles with two blastocysts or four cleavage-stage embryos of good-quality transferred); (vii) patients who received ovarian wedge resection or ovarian drilling. Based on the revised 2003 Rotterdam criteria, four main PCOS phenotypes were identified: phenotype A (HA, OD, and PCOM), phenotype B (HA and OD), phenotype C (HA and PCOM), and phenotype D (OD and PCOM). The detailed diagnostic criteria for HA, OD, and PCOM could be found in Supplementary text. The criteria for good-quality embryos were (i) cleavage-stage embryos: ≥ 7 blastomeres and < 20% fragmentation on day 3 after fertilization [28] (ii) blastocysts: ≥ 3BB on day 5 or day 6 [29]. Written informed consent was obtained from all the patients. Sample size calculation The primary objective of this study was to evaluate whether rsERT-guided personalized embryo transfer could achieve a 25% higher pregnancy rate compared to regular FET in PCOS patients without RIF. Given the absence of specific data on the efficacy of pET in this population, the hypothesis was formulated based on its reported effects in other patient groups, its potential impact, and pregnancy rates observed in PCOS patients. Studies have shown that the incidence of a displaced-WOI ranges in 34–75.14% in patients with RIF [30–32] and from 27% to 65% in those without RIF [32–36]. Moreover, pET has been reported to improve clinical pregnancy rates by 11.35–26.3% [23, 30, 31]. Even in patients who are diagnosed with a receptive endometrium, a timely-refined pET could also improve the intrauterine pregnancy rate (57.38% vs. 44.81%, P = 0.016) [27]. Meanwhile, the reported clinical pregnancy rates in women with PCOS range from 18.2% to 53.3% [37–40]. A 10% cancellation rate was anticipated. Sample size calculation was performed using R version 4.2.3, employing a two-sample proportions test with a two-tailed alpha of 0.05 and a beta of 0.20. Based on this calculation, 62 participants needed to be included per treatment arm, a total of 124 patients. After recruitment, patients were randomized and assigned to each arm in a 1:1 ratio. The simple randomization method was employed in this study by using SPSS 25.0. The attending physician was responsible for enrolling the participants, while another physician managed the randomization process and assigned participants to interventions. No blinding method was implemented in this study. Intervention Patients assigned to the pET group were intended to receive rsERT testing before frozen embryo transfer. For endometrial preparation, either induced-ovulation monitoring or hormone replacement therapy (HRT) was used based on individual evaluation. For HRT, estradiol administration began on the third day of the menstrual cycle, with progesterone added after at least 12 days if the endometrium thickness was > 7 mm and endogenous progesterone (P) levels were near zero. The first day of progesterone supplementation was designated as P + 0, and endometrial biopsies were collected on P + 5. For patients contraindicated for high-dosage estrogen, ovulation induction was administered. Letrozole was given on day 3 of the menstrual cycle for 5 days, with ultrasound monitoring starting on day 10. Plasma luteinizing hormone (LH) levels were dynamically measured when the dominant follicle diameter reached ≥ 16 mm. The LH peak day was recorded as LH + 0, and endometrial biopsies were obtained on LH + 7. Endometrial biopsies were collected from the uterine fundus using a pipeline catheter (AiMu Medical Science & Technology CO.; Liaoning; China) under sterile conditions and then sent for rsERT testing. The rsERT test classifies an endometrial sample as receptive, pre-receptive, or post-receptive based on transcriptomic profiles and provides optimal WOI recommendations with hourly precision. In this study, displaced-WOI was defined as a shift of more than 18 h. Frozen embryo transfer In this study, all patients underwent the transfer of one or two vitrified-thawed embryos. Endometrial preparation involved both induced ovulatory methods and HRT. To ensure consistency, patients who underwent the rsERT test received the same endometrial preparation protocol in the embryo transfer cycle as in the testing cycle. Patients who underwent rsERT testing received embryo transfers timed to align blastocyst transfers with the recommended optimal WOI, while cleavage-stage embryos were transferred 48 h earlier accordingly [23, 34]. For example, if an endometrial biopsy performed at 10:00 a.m. on P + 5 was diagnosed as pre-receptive, with the optimal WOI estimated to occur 6 h later, the blastocyst transfer in the subsequent embryo transfer cycle would be scheduled for 4:00 p.m. on P + 5, with progesterone administration initiated at the same time as in the testing cycle. For cleavage-stage embryo transfers, the corresponding transfer time would be 4:00 p.m. on P + 3. Patients who did not undergo receptivity testing followed the standard embryo transfer schedule. Luteal support protocols were consistent across both groups. Outcome measures and patient follow-up The primary outcome was intrauterine pregnancy, defined as the presence of one or more gestational sacs with a fetal Heartbeat confirmed by ultrasound 28 days after embryo transfer. Secondary outcomes included embryo implantation (the development of the embryo in the uterine lining), early miscarriage (pregnancy loss occurring before 12 weeks of gestation), ectopic pregnancy (a pregnancy in which the embryo implants outside the uterus), and ongoing pregnancy (viable pregnancy at 8–10 weeks’ gestation). The embryo implantation rate was calculated as the number of gestational sacs divided by the total number of transferred embryos. The early miscarriage rate was determined by dividing the number of early miscarriages by the number of intrauterine pregnancies. For all other indicators, the denominator was the number of transfer cycles. All patients were followed up via telephone consultation, with the last follow-up conducted on May 25, 2024. Information, including demographic and clinical data, was either self-reported or extracted from the electronic medical records at our center. Data analysis SPSS Statistics version 25.0 (IBM, USA) and R Studio (Ver 4.3.1) were used for statistical analysis. The Shapiro–Wilk test was used to evaluate the normality of continuous variables. Descriptive statistics were utilized to examine differences between the two groups. Analyses were conducted using intention to treat (ITT) analysis, which includes all participants originally assigned to each arm; per-protocol (PP) analysis, which includes participants who completed the treatment as allocated; and as-treated (AT) analysis, which classifies participants based on the treatment actually received. To address the imbalance in baseline characteristics, propensity score matching (PSM) was performed at a 1:1 ratio. Matching variables included ITT analysis (progesterone level and transferred embryo stage) and AT analysis (homeostatic model assessment of insulin resistance [HOMA-IR], the number of previous failed embryo transfer cycles, the number of previously transferred embryos, the number of transferred embryos, and the transferred embryo stage). Due to the limited sample size, PSM was not applied for the PP analysis as it would have led to excessive data loss and compromised statistical power. Univariate and multivariate binary logistic regression models were performed to assess the association between variables and the primary outcome. Since no single variable was significantly associated with intrauterine pregnancy, the multivariable logistic regression model was adjusted for clinically relevant factors and potential confounders. These included age, body mass index (BMI), HOMA-IR, number of previous failed IVF cycles, PCOS type, whether pET was performed, endometrial thickness on the endometrial transformation day, and the development stage of the transferred embryo. Results were presented as crude or adjusted odds ratios (OR) with 95% confidence intervals (CI). Subgroup analyses were conducted based on BMI, serum testosterone levels, HOMA-IR, number of previous failed embryo transfer cycles, endometrial preparation method, the transferred embryo stage, PCOS type, and the rsERT result within each analysis protocol. The median imputation method was employed to handle missing data. Paired Student’s t-tests, chi-square tests, one-way ANOVA, Kruskal–Wallis tests, and Mann–Whitney U tests were used for comparisons. A P-value < 0.05 was considered statistically significant.

Results

Baseline and clinical characteristics A total of 427 patients were screened for eligibility, with 121 included for randomization and assigned to either the pET arm (n = 61) or the FET arm (n = 60) (Fig. 1). In the pET group, three patients were lost to follow-up post-assignment. Of the remaining patients, 25 opted out of group and requested regular FET. Among the 33 patients who completed the test, 25 proceeded with pET by the final follow-up. In the FET group, 26 patients requested the rsERT test, and of the 34 followed up, 25 proceeded with FET. The ITT analysis was conducted with 99 patients (50 in the pET group and 49 in the FET group), while the PP analysis involved 50 patients (25 in each group). For the AT analysis, terms “rsERT” (n = 49) and “non-rsERT” (n = 50) were used to differentiate between patients who underwent the rsERT test and those who did not. Most baseline characteristics were comparable between the groups, as detailed in Table 1. Most of the patients were diagnosed with primary infertility (n = 80, 80.8%) and had a prolonged duration of infertility, with a median of 51.0 months (IQR 36.0–81.0). According to the Rotterdam criteria, the majority of patients were classified as type D PCOS (80.8%), followed by type A (17.2%) and type C (2.0%), while type B PCOS was not observed. The number of previous failed embryo transfer cycles and the number of previous transferred embryos were comparable between the groups. Table 1. | Variable | Before PSM | After PSM | |||||| |---|---|---|---|---|---|---|---|---| | Overall (n = 99) | FET (n = 49) | pET (n = 50) | P value | Overall (n = 72) | FET (n = 36) | pET (n = 36) | P value | | | Age, year | 30.00 [27.50, 33.00] | 31.00 [28.00, 33.00] | 29.50 [27.25, 32.00] | 0.276 | 30.00 [27.75, 32.25] | 30.50 [27.75, 33.00] | 29.50 [27.50, 32.00] | 0.435 | | BMI, kg/m2 | 23.20 [20.40, 25.00] | 23.30 [21.50, 25.00] | 22.95 [19.52, 24.95] | 0.561 | 22.85 [20.38, 24.42] | 23.10 [20.98, 24.78] | 22.70 [19.58, 24.15] | 0.316 | | Baseline FSH, mIU/ml | 5.69 ± 1.26 | 5.87 ± 1.37 | 5.50 ± 1.14 | 0.149 | 5.65 ± 1.31 | 5.76 ± 1.43 | 5.53 ± 1.18 | 0.461 | | Baseline LH, mIU/ml | 7.60 [5.26, 12.45] | 8.40 [5.90, 11.90] | 6.95 [5.03, 13.20] | 0.332 | 7.45 [5.07, 13.40] | 8.30 [5.62, 13.35] | 6.85 [4.57, 13.40] | 0.362 | | T, ng/ml | 0.37 [0.36, 0.38] | 0.37 [0.35, 0.37] | 0.37 [0.37, 0.42] | 0.287 | 0.37 [0.35, 0.39] | 0.37 [0.34, 0.37] | 0.37 [0.37, 0.44] | 0.130 | | AMH, ng/ml | 7.30 [5.46, 10.83] | 6.97 [5.24, 11.88] | 7.39 [5.60, 10.12] | 0.925 | 7.30 [5.39, 10.77] | 7.04 [5.13, 10.99] | 7.54 [5.51, 10.58] | 0.648 | | HOMA-IR | 2.48 [1.66, 3.59] | 2.48 [1.66, 3.84] | 2.49 [1.65, 3.50] | 0.997 | 2.44 [1.61, 3.76] | 2.42 [1.66, 3.89] | 2.44 [1.43, 3.40] | 0.616 | | Infertility type, n (%) | 0.576 | 1.000 | |||||| | Primary infertility | 80 (80.8) | 38 (77.6) | 42 (84.0) | 59 (81.9) | 30 (83.3) | 29 (80.6) | || | Secondary infertility | 19 (19.2) | 11 (22.4) | 8 (16.0) | 13 (18.1) | 6 (16.7) | 7 (19.4) | || | Infertility duration, month | 51.00 [36.00, 81.00] | 54.00 [42.00, 84.00] | 48.00 [35.25, 80.00] | 0.257 | 53.00 [36.00, 81.00] | 58.50 [46.25, 84.25] | 41.00 [34.75, 78.00] | 0.088 | | IVF indication, n (%) | 0.393 | 0.671 | |||||| | Tubal | 88 (88.9) | 44 (89.8) | 44 (88.0) | 63 (87.5) | 32 (88.9) | 31 (86.1) | || | Male | 6 (6.1) | 2 (4.1) | 4 (8.0) | 5 (6.9) | 2 (5.6) | 3 (8.3) | || | Ovulatory disorder | 3 (3.0) | 1 (2.0) | 2 (4.0) | 3 (4.2) | 1 (2.8) | 2 (5.6) | || | Others | 2 (2.0) | 2 (4.1) | 0 (0.0) | 1 (1.4) | 1 (2.8) | 0 (0.0) | || | PCOS type, n (%)1 | 0.257 | 0.137 | |||||| | A | 17 (17.2) | 7 (14.3) | 10 (20.0) | 14 (19.4) | 4 (11.1) | 10 (27.8) | || | B | 0 (0.0) | 0 (0.0) | 0 (0.0) | - | - | - | || | C | 2 (2.0) | 0 (0.0) | 2 (4.0) | - | - | - | || | D | 80 (80.8) | 42 (85.7) | 38 (76.0) | 58 (80.6) | 32 (88.9) | 26 (72.2) | || | Previous failed IVF cycle, n | 1.00 [1.00, 2.00] | 1.00 [1.00, 2.00] | 1.00 [1.00, 2.00] | 0.404 | 1.00 [1.00, 2.00] | 1.00 [1.00, 2.00] | 1.00 [1.00, 2.00] | 0.835 | | Previous transferred embryos, n | 2.00 [1.00, 3.00] | 2.00 [1.00, 2.00] | 2.00 [1.00, 3.00] | 0.658 | 2.00 [1.00, 3.00] | 2.00 [1.00, 3.00] | 2.00 [1.00, 3.00] | 0.689 | | Endometrial preparation method, n (%) | 0.417 | 0.426 | |||||| | Induced-ovulation | 7 (7.1) | 5 (10.2) | 2 (4.0) | 7 (9.7) | 5 (13.9) | 2 (5.6) | || | HRT | 92 (92.9) | 44 (89.8) | 48 (96.0) | 65 (90.3) | 31 (86.1) | 34 (94.4) | || | Endometrial thickness2, mm | 9.40 [8.60, 10.65] | 9.30 [8.40, 10.60] | 9.40 [8.72, 10.67] | 0.484 | 9.30 [8.60, 10.80] | 9.35 [8.55, 10.83] | 9.30 [8.67, 10.53] | 0.933 | | HRT cycle parameters, | |||||||| | Duration of estradiol administration, day | 13.00 [12.00, 15.00] | 13.00 [12.00, 15.00] | 13.50 [12.00, 15.00] | 0.994 | 13.00 [12.00, 15.00] | 13.00 [12.00, 15.00] | 13.00 [12.00, 14.00] | 0.359 | | Estradiol level, pg/ml | 198.50 [138.60, 353.10] | 198.50 [157.40, 416.80] | 196.80 [128.40, 307.42] | 0.124 | 198.50 [140.35, 335.30] | 198.50 [156.80, 598.28] | 198.50 [128.80, 297.28] | 0.173 | | Progesterone level, ng/ml | 0.20 [0.10, 0.30] | 0.20 [0.10, 0.30] | 0.30 [0.20, 0.38] | 0.005 | 0.20 [0.20, 0.30] | 0.20 [0.20, 0.30] | 0.20 [0.20, 0.30] | 1.000 | | Num. of embryo transferred, n (%) | |||||||| | 1 | 63 (63.6) | 34 (69.4) | 29 (58.0) | 0.333 | 46 (63.9) | 24 (66.7) | 22 (61.1) | 0.806 | | 2 | 36 (36.4) | 15 (30.6) | 21 (42.0) | 26 (36.1) | 12 (33.3) | 14 (38.9) | || | Num. of good-quality embryo transferred, n (%) | 0.189 | 0.916 | |||||| | 0 | 50 (50.5) | 27 (55.1) | 23 (46.0) | 34 (47.2) | 17 (47.2) | 17 (47.2) | || | 1 | 37 (37.4) | 19 (38.8) | 18 (36.0) | 31 (43.1) | 16 (44.4) | 15 (41.7) | || | 2 | 12 (12.1) | 3 (6.1) | 9 (18.0) | 7 (9.7) | 3 (8.3) | 4 (11.1) | || | Transferred embryo stage, n (%) | 0.035 | 1.000 | |||||| | D3 Cleavage embryo | 26 (19.3) | 7 (10.9) | 19 (26.8) | 15 (15.3) | 7 (14.6) | 8 (16.0) | || | D5/6 Blastocysts | 109 (80.7) | 57 (89.1) | 52 (73.2) | 83 (84.7) | 41 (85.4) | 42 (84.0) | 1PCOS phenotypes were categorized as phenotype A (hyperandrogenism, ovulatory dysfunction, and polycystic ovaries), phenotype B (hyperandrogenism and ovulatory dysfunction), phenotype C (hyperandrogenism and polycystic ovaries), and phenotype D (ovulatory dysfunction and polycystic ovaries) 2The endometrial thickness, estradiol, and progesterone levels were measured on the day of endometrial transformation PSM propensity score matching, FET frozen embryo transfer, pET personalized embryo transfer, BMI body mass index, FSH follicular-stimulating hormone, LH luteinizing hormone, T testosterone level, AMH anti-Müllerian hormone, HOMA-IR homeostasis model assessment of insulin resistance, IVF in vitro fertilization, PCOS polycystic ovarian syndrome, HRT hormonal replacement therapy, D day Notably, significantly more blastocysts were transferred in the FET group (89.1% vs. 73.2%, p = 0.035). To further address the imbalance in the progesterone levels on the day of endometrial transformation and the transferred embryo stage, PSM was performed, yielding 36 matched pairs. After PSM, baseline characteristics were well balanced. Clinical outcomes by ITT and PP analysis The embryo implantation rate (IR), intrauterine pregnancy rate (IPR) and ongoing pregnancy rate (OPR) were comparable between the groups in both the ITT and PP analyses, before and after PSM (Table 2, Supplementary Tables 1 and 2). In the ITT analysis before PSM, IR was 54.7% vs. 50.7% (difference, − 4.0% [95% CI, − 20.5 to 12.8%], p = 0.643), IPR was 61.2% vs. 60.0% (difference, − 1.2% [95% CI, − 20.2 to 17.9%], p = 0.901), and OPR was 59.2% vs. 56.0% (difference, − 3.2% [95% CI, − 22.3% to 16.2%], p = 0.749). After the PSM, IR was 54.2% vs. 58.0% (difference, 3.8% [95% CI, − 15.7 to 23.1%], p = 0.702), IPR was 61.1% vs. 66.7% (difference, 5.6% [95% CI, − 16.6 to 27.2%], p = 0.624), and the OPR was 61.1% vs. 63.9% (difference, 2.8% [95% CI, − 19.4 to 24.7%], p = 0.808). In the PP analysis, IR was 54.8% vs. 47.5% (difference, − 7.3% [95% CI, − 29.8 to 16.0%], p = 0.540), IPR was 60.0% vs. 60.0% (difference, 0.0% [95% CI, − 26.6 to 26.6%], p = 1.000), and OPR was 56.0% vs. 56.0% (difference, 0.0% [95% CI, − 26.8 to 26.8%], p = 1.000). Table 2. | Variables | Before PSM | After PSM | |||||| |---|---|---|---|---|---|---|---|---| | FET (n = 49) | pET (n = 50) | Absolute between-group difference, % [95% CI] | P-value | FET (n = 36) | pET (n = 36) | Absolute between-group difference, % [95% CI] | P-value | | | Embryo implantation rate, n (%) | 35/64 (54.7) | 36/71 (50.7) | − 4.0 [−20.5 to 12.8] | 0.643 | 26/48 (54.2) | 29/50 (58.0) | 3.8 [−15.7 to 23.1] | 0.702 | | Intrauterine pregnancy rate, n (%) | 30 (61.2) | 30 (60.0) | − 1.2 [− 20.2 to 17.9] | 0.901 | 22 (61.1) | 24 (66.7) | 5.6 [−16.6 to 27.2] | 0.624 | | Ectopic pregnancy rate, n (%) | 0 (0) | 1 (2.0) | 2.0 [− 5.4 to 10.6] | 1.000 | 0 (0.0) | 1 (2.8) | 2.8 [− 7.1 to 14.3] | 1.000 | | Early miscarriage rate, n (%) | 1 (3.3) | 2 (6.7) | 3.3 [− 11.1 to 18.7] | 1.000 | 0 (0.0) | 1 (4.2) | 4.2 [− 11.3 to 20.5] | 1.000 | | Ongoing pregnancy rate, n (%) | 29 (59.2) | 28 (56.0) | − 3.2 [− 22.3 to 16.2] | 0.749 | 22 (61.1) | 23 (63.9) | 2.8 [− 19.4 to 24.7] | 0.808 | PSM propensity score matching, FET frozen embryo transfer, pET personalized embryo transfer, CI confidence interval Subgroup analyses comparing intrauterine pregnancy rates based on ITT and PP analysis, presented as forest plots in Fig. 2 and Supplementary Fig. 1, revealed no statistically significant differences in IPR within each subgroup. Baseline and clinical characteristics by AT analysis before and after PSM Given that nearly half of the patients did not adhere to the planned protocol, we conducted AT analyses comparing those who received rsERT with those who did not (Supplementary Tables 3 and 4). The rsERT group had significantly higher testosterone levels and lower HOMA-IR levels. Additionally, there was an uneven distribution of PCOS types between the groups. Notably, patients in the rsERT group had significantly more previous failed IVF cycles (2.0 [1.0 to 2.0] vs. 1.0 [1.0 to 1.0], p < 0.001) and a greater number of previously transferred embryos (2.0 [2.0 to 3.0] vs. 1.0 [1.0 to 2.0], p < 0.001). According to rsERT, 21 patients (42.9%) had a displaced-WOI of more than 18 h. A higher proportion of patients in the rsERT group received two embryos transferred compared to the non-rsERT group (49.0% vs. 24.0%, p = 0.018), whereas the number of good-quality embryos transferred and the stage of the transferred embryos were comparable between the groups. No significant differences were observed in IR (54.8% vs. 50.7%, difference, − 4.2% [95% CI, − 20.4 to 12.5%], p = 0.630), IPR (60.0% vs. 61.2%, difference, 1.2% [95% CI, − 17.5 to 19.8%], p = 0.901), and OPR (56.0% vs. 59.2%, difference, 3.2% [95% CI, − 16.2 to 22.3%], p = 0.749). The results of subgroup analyses, presented in Supplementary Fig. 2, showed no significant differences within each subgroup. To address the imbalance in baseline characteristics observed in the AT analysis, PSM was performed, resulting in 18 paired patients in each group. After matching, baseline characteristics were well balanced in the two groups. Still, no significant differences were found in clinical pregnancy outcomes, including IR (58.3% vs. 43.5%, difference, − 14.9% [95% CI, − 41.2 to 13.8%], p = 0.308), IPR (61.1% vs. 50.0%, difference, − 11.1% [95% CI, − 41.2 to 21.1%], p = 0.502), and OPR (55.6% vs. 50.0%, difference, − 5.6% [95% CI, − 36.4 to 26.4%], p = 0.738). Univariate and multivariate binary logistic regression Univariate and multivariate binary logistic regression models were employed to assess the association between pregnancy-related variables and intrauterine pregnancy (Supplementary Table 5, Supplementary Fig. 3). Initially, a univariate regression analysis was conducted, incorporating all relevant parameters, to identify any single variable significantly associated with intrauterine pregnancy. However, none of the variables, including whether pET was performed, demonstrated statistical significance. Given this, a multivariate binary logistic regression model was performed to account for clinically relevant factors and to better control for potential confounders that might influence the primary outcome. After adjusting for confounding factors, the ORs for all the variables remained non-significant, although some notable changes were observed. Certain variables, such as whether pET was performed (adjusted OR 0.631 [95% CI 0.195–2.04] vs. unadjusted OR 1.053 [95% CI 0.470–2.358]) and the transferred embryo stage (adjusted OR 3.253 [95% CI 0.748–14.135] vs. unadjusted OR 1.656 [95% CI 0.532–5.157]), exhibited notable changes in OR, indicating a potential influence.

Discussion

Embryo implantation is a complex, multifactorial process requiring precise coordination between a competent embryo and a receptive endometrium, mediated by hormonal, immune, and molecular signals during the narrow window of implantation [41]. Disruption of this synchronization, often referred to as WOI displacement, has been implicated in implantation failure, with transcriptomic tools identifying such displacement in approximately 25 to 75.14% of patients across various infertility populations [30–33]. pET guided by endometrial receptivity testing has been proposed as a targeted approach to address this issue. To our knowledge, this is the first study to evaluate the clinical utility of transcriptomics-guided pET specifically in infertile women with PCOS but without recurrent implantation failure. Although the study was prospectively registered and followed a pre-defined protocol, substantial protocol deviations occurred, with approximately half of the participants not adhering to their assigned treatment groups. To mitigate potential biases, we employed intention-to-treat (ITT), per protocol (PP), and as-treated (AT) analyses. To further address baseline imbalances and evaluate treatment effects, propensity score matching, binary logistic regression, and sub-group analyses were performed. The study was powered to detect an absolute difference of 25% in intrauterine pregnancy rate between groups based on an ITT framework. The IPR remained consistently statistically non-significant between the groups and sub-groups, both before and after PSM, suggesting the robustness of findings regardless of treatment adherence. Although logistic regression indicated a potential benefit of blastocyst-stage transfers, the wide confidence intervals reflect considerable uncertainty. The persistent lack of statistical significance reflects insufficient power to detect smaller effect sizes, reinforcing the need for cautious interpretation. WOI displacement has been proposed as a potential cause of embryo-endometrium asynchrony, potentially leading to implantation failure even in the presence of a viable embryo. However, both the accurate diagnosis of WOI displacement and the effective implementation of pET remain technically challenging and clinically debated. While pET has shown improved clinical pregnancy rates in RIF patients [31, 42, 43], its efficacy in other contexts remains inconclusive. For instance, in cycles involving euploid blastocyst transfer [36, 44] or unselected patient groups [45, 46], pET did not significantly impact pregnancy outcomes, either positively or negatively, despite a high reported prevalence of displaced WOI. This study did not demonstrate a clear benefit of rsERT-guided pET in improving intrauterine pregnancy rates among PCOS patients without RIF. This may be partially explained by the high proportion of blastocyst-stage and good-quality embryos transferred in both groups. A recent well-designed RCT similarly reported no improvement in pregnancy or live birth rates following pET in patients receiving euploid blastocysts, despite a high incidence of WOI displacement [36]. Consistently, in our cohort, 42.9% of PCOS patients exhibited WOI shifts with over 18 h, yet observed high pregnancy rates regardless of pET, likely owing to the high developmental potential of the transferred embryos. These findings support the hypothesis that successful implantation may occur across a wider temporal window when embryo competence is optimal [47]. Nonetheless, in cases with pronounced WOI displacement or compromised embryo quality, pET may still offer clinical benefit. For instance, He et al. reported significantly improved IPR in patients undergoing day-3 embryo transfer guided by pET, whereas not in patients receiving day-5 embryos [23]. Although our study did not replicate this finding, it underscores the importance of further investigation in well-defined patient subgroups. The impact of PCOS on endometrial function is both complex and heterogeneous. PCOS encompasses four distinct phenotypes with varying degrees of metabolic and hormonal disruption. Among these, hyperandrogenism phenotypes have been associated with impaired decidualization and suboptimal IVF outcomes, underscoring the importance of considering PCOS phenotypes beyond standard diagnostic criteria in future research [39, 48–50]. In this study, the uneven distribution of phenotypes and the absence of phenotype B limited our ability to explore subtype-specific responses. Future trials stratifying patients by PCOS phenotype, particularly hyperandrogenic forms, may yield more clinically relevant insights. In addition, emerging evidence suggests a role for immune-metabolic dysregulation in endometrial dysfunction among PCOS patients. Shared immunometabolism pathways and altered tricarboxylic acid (TCA) cycle metabolites levels have been implicated in both PCOS and RIF, possibly contributing to implantation failure via immune dysregulation [51]. Although immune profiling was not performed in this study, prior research indicates that combining immune-guided and transcriptomics-guided embryo transfer strategies may offer synergistic benefits [31]. This area merits further exploration in PCOS-specific populations. Interesting, the majority of the displacements observed in our cohort were delays (n = 47, 95.9%), consistent with findings by Bellver et al. [52] linking obesity to delayed endometrial maturation. Given the high prevalence of obesity, insulin resistance, and metabolic dysfunction in PCOS, it remains unclear whether WOI delay is a direct consequence of PCOS pathophysiology or a result of its metabolic comorbidities. Future studies with stratified analyses controlling for BMI and metabolic parameters are necessary to disentangle these effects. We acknowledge that treatment deviations may have introduced bias. Patients with more prior IVF failures were more likely to choose pET, whereas others declined due to concerns regarding the invasive procedure or extended treatment time. These factors may have contributed to baseline imbalances and differences in WOI displacement prevalence. Nevertheless, following PSM adjustment, key baseline characteristics were balanced and pregnancy outcomes remained comparable, suggesting the relative robustness of our findings. This study did not demonstrate a benefit of rsERT-guided pET in improving intrauterine pregnancy rates among PCOS patients without RIF in the first embryo transfer cycle. However, the relatively short follow-up period limits our ability to evaluate cumulative or long-term effects. Prior studies have reported higher cumulative pregnancy rates after extended follow-up in pET groups, particularly among patients with marked WOI displacement [35]. Further research with longer observation windows and larger sample sizes is needed to confirm these trends and identify subgroups that may derive meaningful benefit from transcriptomics-guided pET. This study has several limitations. First, a considerable number of patients deviated from the assigned protocols. Patients with more IVF failures and more transferred embryos were more likely to opt for pET, likely due to a stronger desire for pregnancy. Despite employing multiple analytical strategies to adjust for this, residual bias may persist. Second, the lack of blinding may have introduced performance or perception bias; however, ultrasound assessments and embryo transfers were performed by independent clinicians blinded to group assignment, which helps to mitigate this risk. Third, PCOS phenotype distribution was uneven, with one phenotype absent, precluding detailed stratified analysis and potentially masking subtype-specific effects. Finally, we did not assess cumulative pregnancy rates or time to pregnancy, which limits conclusions regarding long-term efficacy. Future studies should investigate whether specific PCOS phenotypes or co-morbidities influence endometrium receptivity and responsiveness to personalized embryo transfer strategies.

Conclusions

Current evidence does not support the routine use of rsERT for personalized embryo transfer in PCOS patients without RIF. Further large-scale, well-designed clinical trials are needed. Supplementary Information Below is the link to the electronic supplementary material. Author contributions CJJ played a key role in the data collection and drafting of the original manuscript. ZJJ and HQ conducted the data analysis. FJ, ZJ, ZQ, and XB assisted in patient recruitment and endometrium sample collection. LH and LYP oversaw the study design, funding acquisition, and reviewed the manuscript. All authors read and approved the final version. Funding This study was funded by the Ministry of Science and Technology of the People’s Republic of China (2021YFC2700404), the National Natural Science Foundation of China (82371682; 82301835), the Fundamental Research Funds for the Central Universities of Central South University (1053320222496), and the Science Foundation of Hunan Province (2024JJ4091; 2023JJ40956). The funders played no role in the study design, data collection, data analysis, data interpretation, or the writing of this manuscript. Data availability The deidentified participant data in this study are not publicly available but may be accessible to qualified researchers upon reasonable request from the corresponding author. Declarations Ethics approval The study protocol as well as the informed consent were approved by the Medical Ethics Committee of Xiangya Hospital (reference number: 202112604–2) and prospectively registered on the Clinical Trial Registry (registration no. ChiCTR2200064131, trial registration date: 2022–09-27). Written informed consent was obtained from all the patients. This study was conducted in accordance with the Declaration of Helsinki. Competing interests The authors declare no competing interests. Footnotes The authors Yanping Li and Hui Li have contributed equally to this work and share correspondence. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Hui Li, Email: [email protected]. Yanping Li, Email: [email protected].

References

- 1.Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–55. [DOI] [PubMed] [Google Scholar] - 2.Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. Fertil Steril. 2012;97(1):28–38. [DOI] [PubMed] [Google Scholar] - 3.Joham AE, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJ, Boyle J, Teede HJ. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022;10(9):668–80. [DOI] [PubMed] [Google Scholar] - 4.Bai X, Zheng L, Li D, Xu Y. Research progress of endometrial receptivity in patients with polycystic ovary syndrome: a systematic review. Reprod Biol Endocrinol. 2021;19(1):122. [DOI] [PMC free article] [PubMed] [Google Scholar] - 5.Palomba S, Falbo A, Russo T, Tolino A, Orio F, Zullo F. Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes. Fertil Steril. 2010;94(5):1805–11. [DOI] [PubMed] [Google Scholar] - 6.Palomba S, de Wilde MA, Falbo A, Koster MP, La Sala GB, Fauser BC. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update. 2015;21(5):575–92. [DOI] [PubMed] [Google Scholar] - 7.Yan L, Wang A, Chen L, Shang W, Li M, Zhao Y. Expression of apoptosis-related genes in the endometrium of polycystic ovary syndrome patients during the window of implantation. Gene. 2012;506(2):350–4. [DOI] [PubMed] [Google Scholar] - 8.Evans J, Salamonsen LA, Winship A, Menkhorst E, Nie G, Gargett CE, Dimitriadis E. Fertile ground: human endometrial programming and lessons in health and disease. Nat Rev Endocrinol. 2016;12(11):654–67. [DOI] [PubMed] [Google Scholar] - 9.Giudice LC. Endometrium in PCOS: implantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab. 2006;20(2):235–44. [DOI] [PubMed] [Google Scholar] - 10.Liu S, Hong L, Lian R, Xiao S, Li Y, Diao L, Zeng Y. Transcriptomic analysis reveals endometrial dynamics in normoweight and overweight/obese polycystic ovary syndrome women. Front Genet. 2022;13: 874487. [DOI] [PMC free article] [PubMed] [Google Scholar] - 11.Sutaji Z, Elias MH, Ahmad MF, Karim AKA, Abu MA. A systematic review and integrated bioinformatic analysis of candidate genes and pathways in the endometrium of patients with polycystic ovary syndrome during the implantation window. Front Endocrinol (Lausanne). 2022;13: 900767. [DOI] [PMC free article] [PubMed] [Google Scholar] - 12.Li J, Jiang X, Li C, Che H, Ling L, Wei Z. Proteomic alteration of endometrial tissues during secretion in polycystic ovary syndrome may affect endometrial receptivity. Clin Proteomics. 2022;19(1): 19. [DOI] [PMC free article] [PubMed] [Google Scholar] - 13.Rashid N, Nigam A, Jain SK, Naqvi SH, Wajid S. Proteomic sift through serum and endometrium profiles unraveled signature proteins associated with subdued fertility and dampened endometrial receptivity in women with polycystic ovary syndrome. Cell Tissue Res. 2020;380(3):593–614. [DOI] [PubMed] [Google Scholar] - 14.Yang X, Xiaoping W, Nan D, Jian Z, Xiaofeng L, Liwei Y, Zhao M, Wang F. Proteomic and bioinformatic analysis of human endometrium from polycystic ovarian syndrome with and without insulin resistance. Gynecol Endocrinol. 2023;39(1): 2173948. [DOI] [PubMed] [Google Scholar] - 15.Zhang J, Ding N, Xin W, Yang X, Wang F. Quantitative proteomics reveals that a prognostic signature of the endometrium of the polycystic ovary syndrome women based on ferroptosis proteins. Front Endocrinol (Lausanne). 2022;13: 871945. [DOI] [PMC free article] [PubMed] [Google Scholar] - 16.Franasiak JM, Ruiz-Alonso M, Scott RT, Simón C. Both slowly developing embryos and a variable pace of luteal endometrial progression may conspire to prevent normal birth in spite of a capable embryo. Fertil Steril. 2016;105(4):861–6. [DOI] [PubMed] [Google Scholar] - 17.Valdes CT, Schutt A, Simon C. Implantation failure of endometrial origin: it is not pathology, but our failure to synchronize the developing embryo with a receptive endometrium. Fertil Steril. 2017;108(1):15–8. [DOI] [PubMed] [Google Scholar] - 18.Khatun M, Meltsov A, Lavogina D, Loid M, Kask K, Arffman RK, Rossi HR, Lättekivi F, Jääger K, Krjutškov K, Rinken A, Salumets A, Piltonen TT. Decidualized endometrial stromal cells present with altered androgen response in PCOS. Sci Rep. 2021;11(1):16287. [DOI] [PMC free article] [PubMed] [Google Scholar] - 19.Li SY, Song Z, Song MJ, Qin JW, Zhao ML, Yang ZM. Impaired receptivity and decidualization in DHEA-induced PCOS mice. Sci Rep. 2016;6:38134. [DOI] [PMC free article] [PubMed] [Google Scholar] - 20.Younas K, Quintela M, Thomas S, Garcia-Parra J, Blake L, Whiteland H, Bunkheila A, Francis LW, Margarit L, Gonzalez D, Conlan RS. Delayed endometrial decidualisation in polycystic ovary syndrome; the role of AR-MAGEA11. J Mol Med (Berl). 2019;97(9):1315–27. [DOI] [PMC free article] [PubMed] [Google Scholar] - 21.Matsuyama S, Whiteside S, Li SY. Implantation and decidualization in PCOS: unraveling the complexities of pregnancy. Int J Mol Sci. 2024;25(2): 1203. [DOI] [PMC free article] [PubMed] [Google Scholar] - 22.Xue Z, Li J, Feng J, Han H, Zhao J, Zhang J, Han Y, Wu X, Zhang Y. Research progress on the mechanism between polycystic ovary syndrome and abnormal endometrium. Front Physiol. 2021;12: 788772. [DOI] [PMC free article] [PubMed] [Google Scholar] - 23.He A, Zou Y, Wan C, Zhao J, Zhang Q, Yao Z, Tian F, Wu H, Huang X, Fu J, Hu C, Sun Y, Xiao L, Yang T, Hou Z, Dong X, Lu S, Li Y. The role of transcriptomic biomarkers of endometrial receptivity in personalized embryo transfer for patients with repeated implantation failure. J Transl Med. 2021;19(1):176. [DOI] [PMC free article] [PubMed] [Google Scholar] - 24.He A, Yang T, Lu S, Zou Y, Wan C, Chen Y, Zhao J, Liu N, Liu D, Li Y, Wang Y, Xu B, Hao J, Fu J, Zhang Q, Wang B, Li Y. Establishment and application of an RNA-seq-based predictive model for the hourly precision window of implantation (WOI) in patients with recurrent implantation failure. J Assist Reprod Genet. 2025;42(6):2067–82. [DOI] [PMC free article] [PubMed] [Google Scholar] - 25.Chen J, He A, Zhang Q, Zhao J, Fu J, Li H, Li Y. The RNA-seq based endometrial receptivity test (rsERT) compared to pinopode: a better diagnostic tool for endometrial receptivity for patients with recurrent implantation failure in Chinese population. Front Endocrinol (Lausanne). 2022;13: 1009161. [DOI] [PMC free article] [PubMed] [Google Scholar] - 26.Huang X, Fu J, Zhang Q, Zhao J, Yao Z, Xia Q, Tang H, Xu A, He A, Liang S, Lu S, Li Y. Integrated treatment guided by RNA-seq-based endometrial receptivity assessment for infertility complicated by MEN1. Front Endocrinol (Lausanne). 2023;20(14):1224574. [DOI] [PMC free article] [PubMed] [Google Scholar] - 27.Yang T, Hou Z, Zhang Q, Zhao J, Liu N, Liu D, Li Y, Wang Y, Xu B, Zou Y, Wan C, Li Y. Personalized embryo transfer guided by rsERT with hourly precision improves pregnancy outcomes in patients with a receptive window of implantation: a pilot study. J Assist Reprod Genet. 2024;41(10):2657–65. [DOI] [PMC free article] [PubMed] [Google Scholar] - 28.Alpha Scientists in Reproductive Medicine, ESHRE Special Interest Group of Embryology. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod. 2011;26(6):1270–83. [DOI] [PubMed] [Google Scholar] - 29. Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB. Reprint of: Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer. Fertil Steril. 2019;112(4 Suppl1):e81-e84. [DOI] [PubMed] - 30. Ohara Y, Matsubayashi H, Suzuki Y, Takaya Y, Yamaguchi K, Doshida M, Takeuchi T, Ishikawa T, Handa M, Miyake T, Takiuchi T, Kimura T. Clinical relevance of a newly developed endometrial receptivity test for patients with recurrent implantation failure in Japan. Reprod Med Biol. 2022 7;21(1):e12444. [DOI] [PMC free article] [PubMed] - 31.Jia Y, Huang Y, Ai ZH, Dong YJ, Guo YH, Yang Y, Zhang D, Ye HX, Yang J. Exploring the effectiveness of endometrial receptivity array and immune profiling in patients with multiple implantation failure: a retrospective cohort study based on propensity score matching. J Reprod Immunol. 2024;163: 104218. [DOI] [PubMed] [Google Scholar] - 32.Liu Z, Liu X, Wang M, Zhao H, He S, Lai S, Qu Q, Wang X, Zhao D, Bao H. The clinical efficacy of personalized embryo transfer guided by the endometrial receptivity array/analysis on IVF/ICSI outcomes: a systematic review and meta-analysis. Front Physiol. 2022;27(13): 841437. [DOI] [PMC free article] [PubMed] [Google Scholar] - 33. Place TL, Agarwal R, Najafzadeh P, Walia S, McGinnis LK, Kohli P, Felix JC, Paulson RJ. Consistency of endometrial receptivity array and histologic dating of spatially distinct endometrial samplings: a prospective, blinded study. F S Rep. 2023 26;4(4):375–379. [DOI] [PMC free article] [PubMed] - 34.Bergin K, Eliner Y, Duvall DW Jr, Roger S, Elguero S, Penzias AS, Sakkas D, Vaughan DA. The use of propensity score matching to assess the benefit of the endometrial receptivity analysis in frozen embryo transfers. Fertil Steril. 2021;116(2):396–403. [DOI] [PubMed] [Google Scholar] - 35.Simón C, Gómez C, Cabanillas S, Vladimirov I, Castillón G, Giles J, Boynukalin K, Findikli N, Bahçeci M, Ortega I, Vidal C, Funabiki M, Izquierdo A, López L, Portela S, Frantz N, Kulmann M, Taguchi S, Labarta E, Colucci F, Mackens S, Santamaría X, Muñoz E, Barrera S, García-Velasco JA, Fernández M, Ferrando M, Ruiz M, Mol BW, Valbuena D, ERA-RCT Study Consortium Group. A 5-year multicentre randomized controlled trial comparing personalized, frozen and fresh blastocyst transfer in IVF. Reprod Biomed Online. 2020;41(3):402–15. [DOI] [PubMed] [Google Scholar] - 36.Doyle N, Jahandideh S, Hill MJ, Widra EA, Levy M, Devine K. Effect of timing by endometrial receptivity testing vs standard timing of frozen embryo transfer on live birth in patients undergoing in vitro fertilization: a randomized clinical trial. JAMA. 2022;328(21):2117–25. [DOI] [PMC free article] [PubMed] [Google Scholar] - 37.Eftekhar M, Mirhashemi ES, Tabibnejad N. Assisted reproductive outcomes in women with different polycystic ovary syndrome phenotypes. Int J Gynaecol Obstet. 2019;144(2):147–52. [DOI] [PubMed] [Google Scholar] - 38.Kuivasaari-Pirinen P, Hippeläinen M, Hakkarainen H, Randell K, Heinonen S. Cumulative baby take-home rate among women with PCOS treated by IVF. Gynecol Endocrinol. 2010;26(8):582–9. [DOI] [PubMed] [Google Scholar] - 39.Ramezanali F, Ashrafi M, Hemat M, Arabipoor A, Jalali S, Moini A. Assisted reproductive outcomes in women with different polycystic ovary syndrome phenotypes: the predictive value of anti-Müllerian hormone. Reprod Biomed Online. 2016;32(5):503–12. [DOI] [PubMed] [Google Scholar] - 40.Salemi S, Yahyaei A, Vesali S, Ghaffari F. Endometrial preparation for vitrified-warmed embryo transfer with or without GnRH-agonist pre-treatment in patients with polycystic ovary syndrome: a randomized controlled trial. Reprod Biomed Online. 2021;43(3):446–52. [DOI] [PubMed] [Google Scholar] - 41.Zhang S, Lin H, Kong S, Wang S, Wang H, Wang H, Armant DR. Physiological and molecular determinants of embryo implantation. Mol Aspects Med. 2013;34(5):939–80. [DOI] [PMC free article] [PubMed] [Google Scholar] - 42.Díaz-Gimeno P, Ruiz-Alonso M, Blesa D, Bosch N, Martínez-Conejero JA, Alamá P, Garrido N, Pellicer A, Simón C. The accuracy and reproducibility of the endometrial receptivity array is superior to histology as a diagnostic method for endometrial receptivity. Fertil Steril. 2013;99(2):508–17. [DOI] [PubMed] [Google Scholar] - 43.Hashimoto T, Koizumi M, Doshida M, Toya M, Sagara E, Oka N, Nakajo Y, Aono N, Igarashi H, Kyono K. Efficacy of the endometrial receptivity array for repeated implantation failure in Japan: a retrospective, two-centers study. Reprod Med Biol. 2017;16(3):290–6. [DOI] [PMC free article] [PubMed] [Google Scholar] - 44.Chae-Kim J, Doyle N, Jahandideh S, O’Brien JE, Widra EA, Levy M, DeCherney AH, Devine K, Hill MJ. Evaluating the endometrial receptivity assay: a nested diagnostic accuracy study within the synchrony randomized clinical trial. Fertil Steril. 2023;120(6):1255–6. [DOI] [PubMed] [Google Scholar] - 45.Arian SE, Hessami K, Khatibi A, To AK, Shamshirsaz AA, Gibbons W. Endometrial receptivity array before frozen embryo transfer cycles: a systematic review and meta-analysis. Fertil Steril. 2023;119(2):229–38. [DOI] [PubMed] [Google Scholar] - 46.Riestenberg C, Kroener L, Quinn M, Ching K, Ambartsumyan G. Routine endometrial receptivity array in first embryo transfer cycles does not improve live birth rate. Fertil Steril. 2021;115(4):1001–6. [DOI] [PubMed] [Google Scholar] - 47.Teh WT, McBain J, Rogers P. What is the contribution of embryo-endometrial asynchrony to implantation failure? J Assist Reprod Genet. 2016;33(11):1419–30. [DOI] [PMC free article] [PubMed] [Google Scholar] - 48.Ma L, Cao Y, Ma Y, Zhai J. Association between hyperandrogenism and adverse pregnancy outcomes in patients with different polycystic ovary syndrome phenotypes undergoing in vitro fertilization/intracytoplasmic sperm injection: a systematic review and meta-analysis. Gynecol Endocrinol. 2021;37(8):694–701. [DOI] [PubMed] [Google Scholar] - 49.Wongwananuruk T, Sato T, Kajihara T, Matsumoto S, Akita M, Tamura K, Brosens JJ, Ishihara O. Endometrial androgen signaling and decidualization regulate trophoblast expansion and invasion in co-culture: a time-lapse study. Placenta. 2016;47:56–62. [DOI] [PubMed] [Google Scholar] - 50.De Vos M, Pareyn S, Drakopoulos P, Raimundo JM, Anckaert E, Santos-Ribeiro S, Polyzos NP, Tournaye H, Blockeel C. Cumulative live birth rates after IVF in patients with polycystic ovaries: phenotype matters. Reprod Biomed Online. 2018;37(2):163–71. [DOI] [PubMed] [Google Scholar] - 51.Chen W, Yang Q, Hu L, Wang M, Yang Z, Zeng X, Sun Y. Shared diagnostic genes and potential mechanism between PCOS and recurrent implantation failure revealed by integrated transcriptomic analysis and machine learning. Front Immunol. 2023;14(16): 1175384. [DOI] [PMC free article] [PubMed] [Google Scholar] - 52.Bellver J, Marín C, Lathi RB, Murugappan G, Labarta E, Vidal C, Giles J, Cabanillas S, Marzal A, Galliano D, Ruiz-Alonso M, Simón C, Valbuena D. Obesity affects endometrial receptivity by displacing the window of implantation. Reprod Sci. 2021;28(11):3171–80. [DOI] [PubMed] [Google Scholar] Associated Data This section collects any data citations, data availability statements, or supplementary materials included in this article. Supplementary Materials Data Availability Statement The deidentified participant data in this study are not publicly available but may be accessible to qualified researchers upon reasonable request from the corresponding author.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

MeSH descriptors

Embryo Implantation Embryo Implantation Embryo Transfer Embryo Transfer Endometrium Endometrium Endometrium Infertility, Female Infertility, Female Infertility, Female Polycystic Ovary Syndrome Polycystic Ovary Syndrome Polycystic Ovary Syndrome Polycystic Ovary Syndrome RNA-Seq RNA-Seq Adult Female Fertilization in Vitro Fertilization in Vitro

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-11-15T09:34:25.365398+00:00
pubmed
last seen: 2026-10-08T21:51:28.594230+00:00
unpaywall
last seen: 2026-11-21T07:40:41.001492+00:00